Ground-breaking LSD Microdosing for Alzheimer’s Study

This research, which is grounded in solid pre-clinical and anecdotal evidence, offers a new hope for improving the quality-of-life of people suffering from dementia and that of their caregivers, and possibly for slowing, or even reversing, the progression of Alzheimer’s disease (AD) and other related forms of dementia.

Project highlights

  • First ever clinical study of LSD microdosing for Alzheimer’s disease.
  • Strong pre-clinical and anecdotal evidence to support the study.
  • Collaboration with the distinguished Head of Geriatrics at the University of Basel.
  • Will pave the way to clinical research in this area of high unmet need.
  • High potential for positive societal impact.



Case Study

In 2021, Amanda received the most astonishing report concerning a 97-year old lady (SR) diagnosed with Alzheimer’s disease and vascular dementia at the age of 88. When her condition deteriorated substantially, her caregiver, with the agreement of her family, decided to determine whether microdoses of LSD might help spring her out of her deep apathetic state. According to SR’s caregiver, the effects were nothing short of remarkable, restoring SR to a full state of awareness, with presence of mind, wit, and personality.

Scientific Evidence

Our research has demonstrated the potential for psychedelics, particularly LSD, to increase the expression of proteins involved in the growth of new synapses and to enhance memory and exploratory behaviour in animals. Our microdosing research has also shown that low doses of LSD can increase the level of BDNF, a key protein involved in neuroplasticity, which patients with Alzheimer’s produce at reduced levels. Taken together, our results suggest that LSD could possibly slow or even reverse the effects of Alzheimer’s disease, even at doses that would not produce strong psychoactive effects.

LSD Microdosing for Alzheimer’s Disease


To be announced soon.